What is Antegenes?
Antegenes is at the forefront of precision prevention healthcare, specializing in personalized cancer risk assessment via advanced genetic testing. The company offers accessible at-home genetic tests designed to evaluate polygenic cancer risk, subsequently providing individuals with meticulously tailored prevention plans. These services, developed in collaboration with leading medical professionals, cater to both men and women across a spectrum of cancer types. Antegenes' mission is to revolutionize cancer prevention and care, aiming to substantially decrease mortality rates through early detection and individualized medical strategies.
How much funding has Antegenes raised?
Antegenes has raised a total of $3.9M across 1 funding round:
Angel/Seed
$3.9M
Angel/Seed (2022): $3.9M with participation from Enterprise Estonia, Timo Rein, and European Institute of Innovation and Technology
Key Investors in Antegenes
Enterprise Estonia
Enterprise Estonia, operating as Trade with Estonia, is a government agency dedicated to fostering international business relationships with Estonian companies. It provides crucial insights into Estonia's dynamic economy and innovative sectors, aiming to connect global firms with leading businesses across healthtech and other high-growth industries.
Timo Rein
Timo Rein is an individual investor who participated in Antegenes' funding round. Further details on their investment focus are not publicly available.
European Institute of Innovation and Technology
The European Institute of Innovation and Technology (EIT) is a body of the European Union established to stimulate innovation and entrepreneurship across Europe. Its participation in Antegenes' funding round indicates a strategic interest in advancing healthtech innovation within the EU.
What's next for Antegenes?
The recent major strategic investment positions Antegenes for significant expansion and further development in the precision prevention sector. This capital infusion is expected to accelerate the company's growth, enhance its technological capabilities in genetic analysis, and broaden its market reach. The strategic nature of this financing suggests a focus on scaling operations, forging key partnerships within the healthcare ecosystem, and potentially exploring new therapeutic avenues or diagnostic tools. Antegenes is poised to solidify its leadership in personalized cancer prevention, driving innovation and improving patient outcomes.
See full Antegenes company page
